# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Reuters
- Reuters
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the b...